Trial
NCT01111058
Everolimus Versus Placebo in Head and Neck Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Chicago
Collaborators
Novartis Pharmaceuticals
Condition
Head and Neck Cancer
Intervention
Everolimus (RAD 001)
Why stopped
Slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-04-07